10-KPeriod: FY2020

STRYKER CORP Annual Report, Year Ended Dec 31, 2020

Filed February 11, 2021For Securities:SYK

Summary

Stryker Corporation's 2020 10-K filing reveals a company navigating the complexities of the COVID-19 pandemic, which led to a 3.6% decline in net sales compared to 2019. Despite this, Stryker demonstrated resilience through strategic acquisitions, notably the significant purchase of Wright Medical Group N.V., which expanded its portfolio in trauma and extremities. The company maintained a strong focus on its core segments: Orthopaedics, MedSurg, and Neurotechnology and Spine, with MedSurg representing the largest segment by sales in 2020. Financially, Stryker reported net earnings of $1.6 billion, a decrease from the previous year, impacted by pandemic-related disruptions and increased interest expenses due to debt financing for acquisitions. However, operating cash flow remained robust, and the company prioritized its capital allocation strategy by investing heavily in acquisitions and continuing dividend payments, while suspending share repurchases for 2020 and 2021. Management highlighted the successful integration of acquisitions and ongoing efforts to drive innovation and operational efficiency amidst evolving market conditions and regulatory landscapes.

Financial Highlights

52 data points
Beta

Revenue

$14.35B

63.1% Gross Margin

Net Income

$1.60B

11.1% Net Margin

EPS (Diluted)

$4.20

Total Assets

$34.33B

Cash & Equivalents

$2.94B

Free Cash Flow

$2.79B

Financial Statements
Beta
Revenue$14.35B
Cost of Revenue$5.29B
Gross Profit$9.06B
R&D Expenses$984.00M
SG&A Expenses$5.36B
Operating Expenses$6.83B
Operating Income$2.22B
Interest Expense$315.00M
Net Income$1.60B
EPS (Basic)$4.26
EPS (Diluted)$4.20
Shares Outstanding (Basic)375.50M
Shares Outstanding (Diluted)380.30M

Key Highlights

  • 1Net sales decreased by 3.6% to $14.35 billion in 2020, primarily due to the impact of the COVID-19 pandemic on elective medical procedures.
  • 2The company completed a significant acquisition of Wright Medical Group N.V. for $4.1 billion, strengthening its position in trauma and extremities.
  • 3MedSurg remained the largest segment by net sales ($6.4 billion), followed by Orthopaedics ($4.96 billion) and Neurotechnology and Spine ($2.99 billion).
  • 4Net earnings declined to $1.6 billion ($4.20 per diluted share) from $2.1 billion ($5.48 per diluted share) in 2019, impacted by pandemic-related challenges and acquisition financing.
  • 5Stryker invested $4.2 billion in acquisitions in 2020, demonstrating a commitment to growth through strategic M&A.
  • 6Operating cash flow was strong at $3.3 billion, supporting the company's liquidity and investment strategies.
  • 7The company suspended its share repurchase program through 2021, prioritizing other capital allocation strategies like acquisitions and dividends.

Frequently Asked Questions

The COVID-19 pandemic significantly impacted Stryker's 2020 financial performance, leading to a 3.6% decrease in net sales. This was primarily due to the suspension of elective medical procedures, which are crucial for many of Stryker's products, particularly in the Orthopaedics segment. The pandemic also caused disruptions in supply chains and manufacturing operations.

Stryker made a significant strategic move by acquiring Wright Medical Group N.V. for $4.1 billion. This acquisition was a key focus, strengthening Stryker's global market position, especially in trauma and extremities within the Orthopaedics segment. Another acquisition in 2020 was OrthoSensor, Inc., which focuses on digital musculoskeletal care and sensor technology for joint replacements.

In 2020, the MedSurg segment generated the highest net sales at $6.4 billion, making it the largest segment. The Orthopaedics segment reported $4.96 billion in net sales, while the Neurotechnology and Spine segment had $2.99 billion. All segments experienced declines in net sales due to the pandemic's impact on elective procedures and market demand, with Orthopaedics seeing a notable decrease of 5.6%.

Stryker maintained a strong financial position with $3.02 billion in cash, cash equivalents, and marketable securities as of December 31, 2020. Operating cash flow was robust at $3.28 billion, indicating a healthy ability to generate cash from its core operations. The company had access to significant credit facilities and maintained investment-grade debt ratings, suggesting good liquidity and financial flexibility to navigate market challenges and fund future growth.